At a glance
ClinicalIndex Comparison Record- ✓Pathology-proven locally advanced or metastatic malignant disease no longer benefitting from standard treatment or for which no standard treatment is available/indicated
- ✓Measurable or evaluable disease per RECIST v1.1, IMWG, CHESON/Lugano, RANO, iRECIST, or IWG criteria depending on tumor type
- ✓Genomic profile with actionable variant or protein overexpression for which an approved targeted therapy in the study has potential clinical benefit
- ✓Genomic/molecular test from preapproved laboratory; may be performed on fresh or paraffin-embedded tumor specimen or cell-free DNA from liquid biopsy
- ✕Eligible for other ongoing trials with equal or greater potential benefit where access is manageable
- ✕Ongoing toxicity >CTCAE grade 2 related to prior anti-tumor treatment completed within 4 weeks, or peripheral neuropathy ≥CTCAE grade 3
- ✕Progressive brain metastases or declining neurologic function; treated/stable brain metastases are eligible
- ✕For GBM patients: requirement for enzyme-inducing antiepileptic drugs (EIAED); must switch to non-EIAED at least 2 weeks prior to randomization
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Improving Public Cancer Care by Implementing Precision Medicine in Norway A Multi-cohort Phase 2 Treatment Clinical Study Investigating Efficacy of Approved Drugs Outside Indication in Patients With Advanced Cancer
In Brief
A Phase 2 clinical trial evaluating Atezolizumab for Cancer Metastatic. Currently recruiting, targeting 3,000 participants across 17 sites.
Signals
Detailed Summary
IMPRESS-Norway is a prospective, non-randomized clinical trial evaluating efficacy of commercially available, anti-cancer drugs prescribed for patients with advanced cancer diagnosed with potentially actionable alterations as revealed by molecular diagnostics. IMPRESS-Norway is a nation-wide study and all hospitals with an oncology and / or hematology department will be invited to participate in the study. The study will use a combined umbrella and basket design and a Simon two-stage model of expanding cohorts to follow up potentially effective combinations of biomarker and drug on specific indications. Sampling of biological material will be performed at presentation, during treatment and upon progression. Additional biomarker and translational analyses including whole genome sequencing (WGS) on tumour material and liquid biopsies, identifying mechanisms underlying drug sensitivity versus resistance will be performed.
Study Details
Timeline
Interventions
drugs used outside indication, based on biomarker